Navigation Links
Harrisvaccines Awarded Vaccine Product Licensure
Date:9/20/2012

AMES, Iowa, Sept. 20, 2012 /PRNewswire/ -- Harrisvaccines announces United States Department of Agriculture (USDA) licensure of the company's swine flu vaccine, approved by the Department's Center for Veterinary Biologics (CVB) for disease caused by swine influenza virus (SIV) H3N2.

The vaccine is the first to be licensed by the USDA CVB that utilizes RNA Particle Technology. Dr. Kurt Kamrud, Vice President of Research and Chief Scientific Officer at Harrisvaccines, led the company's development and application of RNA Particle Technology - with the ultimate goal of producing a swine influenza vaccine that could be manufactured faster and safer than those produced using modified live or inactivated/killed virus technologies.

This groundbreaking platform allows for the manufacture of vaccines without ever isolating a live virus from infected animals. Only a gene from an infected animal is required to prepare vaccines in as little as four weeks.  The vaccine, licensed as Swine Influenza Vaccine, RNA, Product Code 19A5.D0, was initially submitted to USDA CVB for licensing in 2009.

"When we submitted our license application in 2009, the USDA didn't have an established category into which the product fit," said Jodi French, USDA Liaison at Harrisvaccines.  "There were additional regulatory hoops to jump through in order to achieve this first license."

In addition to USDA licensure of the vaccine, Harrisvaccines received a United States Veterinary Biologics Establishment License, #592, which approves the Ames-based facility for future manufacture of new vaccines for a broader spectrum of veterinary applications, from swine and cattle to companion animal and farmed aquaculture. 

"We were founded in 2006, so this has been a long, challenging road to licensure for a novel technology to be used in animal health," Harrisvaccines founder and President Dr. D.L. "Hank" Harris said. "These USDA licenses mark a major milestone, and perhaps most importantly, signal that this technology is a key fixture in our country's continuing fight against biological threats and ever-changing pathogens."

"With USDA licensure of both the SIV H3N2 vaccine and our Ames manufacturing facility, we expect additional licenses for vaccines manufactured using RNA Particle Technology to be issued on more condensed timelines. With new strains of this virus identified as recently as July of this year, we're particularly interested in our potential to manufacture custom, farm-specific vaccines in a matter of weeks instead of months," Harris said.

About Harrisvaccines

Headquartered in Ames, Iowa, Harrisvaccines focuses on improving animal health and enhancing productivity in the swine, cattle, equine and farmed shrimp industries. Harrisvaccines employs two unique RNA platforms to develop custom farm-specific vaccine products against animal diseases. For more information, visit www.harrisvaccines.com.


'/>"/>
SOURCE Harrisvaccines
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Healionics Awarded $900k Grant from NIH
2. Eutropics Pharmaceuticals awarded NCI contract to develop companion diagnostic for guiding AML treatments
3. Managed Health Care Associates, Inc. (MHA) Awarded Commonwealth of Massachusetts GPO Contract
4. Sequent Medical, Inc. Awarded U.S. Patent for MicroBraid Technology
5. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
6. ChanTest Awarded $1 Million Grant for Predictive Assays using Stem Cell-Derived Human Cardiomyocytes
7. Elusys Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax
8. Antigen Discovery Inc. Awarded Phase I SBIR Grant to Develop a Fully Integrated Microfluidic Point of Care Diagnostic Device
9. Antigen Discovery, Inc. Awarded Phase II SBIR Grant to Identify Biomarkers Associated with Protection against Malaria
10. Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)
11. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... FinancialBuzz.com News Commentary   ... Medical cannabis products around the world are projected to gain popularity. A ... market will reach a value of USD 55.8 billion by 2025. ... growing industry. By the end of 2016, 28 states have now laws ... conservative states like Arkansas and North ...
(Date:3/24/2017)... -- Global Ampoules Market report provides a ... and industry chain structure. The Ampoules market analysis is ... landscape analysis, and major regions, development status. ... Complete ... 10 company profiles and 183 tables and figures is ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly and ... plans to invest $850 million in its U.S. ... across its U.S. enterprise, including research laboratories, manufacturing ... are being driven by demand for Lilly products, ... medicines in development targeting cancer, pain, diabetes and ...
Breaking Medicine Technology:
(Date:3/25/2017)... , ... March 25, 2017 , ... Getting earned media ... public relations partner. , All through the year, Garden Media aims to provide ... working with key influencers and pitching client’s key messages to gain coveted ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease ... hospitals in the United States, it’s a threat that is constantly changing and ... infection prevention and offers strategies for the healthcare community to help decrease the ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... The iaedp ... and other medical professionals caring for those suffering from the full spectrum of disordered ... 800, as eating disorders professionals from nearly all 50 states and several countries converged ...
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... of enhancements, upgrading their training and leads programs. , In February, 2017, Empower ... elite sales agents, Performance Partners is designed to teach how to maximize their ...
Breaking Medicine News(10 mins):